Study on gallbladder cancer adjuvant therapy

doi:10.16139/j.1007-9610.2021.02.015

Abstract

CLC Number:

R735.8

CAI Chen, GONG Wei. Study on gallbladder cancer adjuvant therapy[J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 167-170.

References 33

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2]	Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome[J]. Clin Epidemiol, 2014, 6:99-109.
[3]	Goetze TO. Gallbladder carcinoma: prognostic factors and therapeutic options[J]. World J Gastroenterol, 2015, 21(43):12211-12217.
[4]	Rawla P, Sunkara T, Thandra KC, et al. Epidemiology of gallbladder cancer[J]. Clin Exp Hepatol, 2019, 5(2):93-102.
[5]	Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5):E359-E386.
[6]	任泰, 李永盛, 耿亚军, 等. 中国2010—2017年胆囊癌治疗模式及预后分析[J]. 中华外科杂志, 2020, 58(9):E008.
[7]	Chaudhari VA, Ostwal V, Patkar S, et al. Outcome of neoadjuvant chemotherapy in “locally advanced/borderline resectable” gallbladder cancer: the need to define indications[J]. HPB (Oxford), 2018, 20(9):841-847.
[8]	Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14):1273-1281.
[9]	胆道肿瘤专家委员会. CSCO胆道系统肿瘤诊断治疗专家共识(2019年版)[J]. 临床肿瘤学杂志, 2019, 24(9):828-838.
[10]	Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer(BILCAP): a randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019, 20(5):663-673. doi: S1470-2045(18)30915-X pmid: 30922733
[11]	Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? a phase Ⅲ multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma[J]. Cancer, 2002, 95(8):1685-1695.
[12]	Edeline J, Benabdelghani M, Bertaut A, et al. Gem-citabine and oxaliplatin chemotherapy or surveillance in resected biliary tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase Ⅲ study[J]. J Clin Oncol, 2019, 37(8):658-667. doi: 10.1200/JCO.18.00050 pmid: 30707660
[13]	Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase Ⅲ clinical trial[J]. Ann Oncol, 2019, 30(12):1950-1958. doi: S0923-7534(20)32557-6 pmid: 31987298
[14]	Gebbia V, Giuliani F, Maiello E, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase Ⅱ study[J]. J Clin Oncol, 2001, 19(20):4089-4091. pmid: 11600613
[15]	Nehls O, Klump B, Arkenau HT, et al. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase Ⅱ trial[J]. Br J Cancer, 2002, 87(7):702-704.
[16]	Alberts SR, Al-Khatib H, Mahoney MR, et al. Gem-citabine, 5-fluorouracil, and leucovorin in advanced bi-liary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase Ⅱ trial[J]. Cancer, 2005, 103(1):111-118. pmid: 15558814
[17]	Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase Ⅱ trial[J]. J Clin Oncol, 2005, 23(10):2332-2338.
[18]	Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase Ⅱ trial[J]. Br J Cancer, 2008, 98(2):309-315.
[19]	Zhang W, Du C, Sun Y, et al. Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase Ⅱ trial[J]. Cancer Chemother Pharmacol, 2018, 82(4):655-660.
[20]	Sahai V, Catalano PJ, Zalupski MM, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial[J]. JAMA Oncol, 2018, 4(12):1707-1712.
[21]	Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial[J]. JAMA Oncol, 2019, 5(6):824-830.
[22]	Yoo C, Han B, Kim HS, et al. Multicenter phase Ⅱ study of oxaliplatin, irinotecan, and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract cancer[J]. Cancer Res Treat, 2018, 50(4):1324-1330.
[23]	Wang J, Narang AK, Sugar EA, et al. Evaluation of adjuvant radiation therapy for resected gallbladder carcinoma: a multi-institutional experience[J]. Ann Surg Oncol, 2015, 22(Suppl 3):S1100-S1106.
[24]	Mojica P, Smith D, Ellenhorn J. Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease[J]. J Surg Oncol, 2007, 96(1):8-13. pmid: 17516546
[25]	Hyder O, Dodson RM, Sachs T, et al. Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: a propensity score-matched surveillance, epidemiology, and end results analysis[J]. Surgery, 2014, 155(1):85-93.
[26]	Mantripragada KC, Hamid F, Shafqat H, et al. Adjuvant therapy for resected gallbladder cancer: analysis of the national cancer data base[J]. J Natl Cancer Inst, 2017, 109(2):djw202.
[27]	Hoehn RS, Wima K, Ertel AE, et al. Adjuvant therapy for gallbladder cancer: an analysis of the national cancer data base[J]. J Gastrointest Surg, 2015, 19(10):1794-1801.
[28]	Ghidini M, Tomasello G, Botticelli A, et al. Adjuvant chemotherapy for resected biliary tract cancers: a syste-matic review and meta-analysis[J]. HPB (Oxford), 2017, 19(9):741-748.
[29]	Valle JW, Lamarca A, Goyal L, et al. New horizons for precision medicine in biliary tract cancers[J]. Cancer Discov, 2017, 7(9):943-962. doi: 10.1158/2159-8290.CD-17-0245 pmid: 28818953
[30]	Verlingue L, Malka D, Allorant A, et al. Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial[J]. Eur J Cancer, 2017, 87:122-130. doi: S0959-8049(17)31353-9 pmid: 29145038
[31]	Sun D, Ma J, Wang J, et al. Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer[J]. Cancer Immunol Immunother, 2019, 68(9):1527-1535.
[32]	Chen X, Wu X, Wu H, et al. Camrelizumab plus gem-citabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase Ⅱ trial[J]. J Immunother Cancer, 2020, 8(2):e001240.
[33]	Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J]. JAMA Oncol, 2020, 6(6):888-894.

Study on gallbladder cancer adjuvant therapy

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 33

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHANG Hongzhan, ZHANG Kai. Current status and prospect of endoscopic photodynamic therapy for unresectable extrahepatic cholangiocarcinoma and ampullary carcinoma [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 316-320.
[2]	ZHU Siwei, YIN Xinmin. Laparoscopic radical resection of hilar cholangiocarcinoma: current status and considerations [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 100-103.
[3]	LI Xiangcheng, CHEN Yananlan, LI Changxian. Vascular reconstruction in radical resection for hilar cholangiocarcinoma [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 104-109.
[4]	XING Ying, CHENG Shi. Neoadjuvant therapy for gallbladder cancer: current status and challenge [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 110-114.
[5]	LUO Fangxiu, MA Qianchen, YUAN Fei. The fifth edition of WHO classification of digestive system tumors: update and progress on biliary system tumors [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 124-131.
[6]	WANG Yuanjiang, ZOU Hao. Clinical study on comprehensive treatment of gallbladder cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 171-176.
[7]	CHEN Xuanwu, YANG Chuanyu, JIANG Minjie, DU Weidong. Progress of study on gallbladder adenomyomatosis: pathogenesis, diagnosis and treatment [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 87-90.
[8]	WANG Kaiyu, WANG Liang, SHU Bin, ZHANG Yuewei, HUANG Xin, GE Xiaqing, XIAO Ming, ZHANG Qijia, YAN Zhe, SONG Yan, XIANG Canhong. Radical resection of hilar cholangiocarcinoma combined with left hepatectomy and resection of ventral segment of right anterior sector: one case report [J]. Journal of Surgery Concepts & Practice, 2021, 26(05): 441-444.
[9]	WU Wenta, LI Wei, CAO Yijun. Diagnosis and treatment of xanthogranulomatous cholecystitis [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 271-274.
[10]	LÜ Tianrun, LI Fuyu. Is there a era of minimally invasive surgery for gallbladder cancer [J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 174-178.
[11]	ZHANG Rui, SU Jingbo, ZHANG Jian, GENG zhimin. Biliary tract carcinoma: from clinical classification to molecular classification [J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 97-102.
[12]	WANG Jian, YANG Chuanxin. Perihilar surgery: difficulty and strategy in management [J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 93-96.
[13]	WU Gang, CAI Duan. Surgical treatment of gallbladder polyp: controversy and strategy [J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 107-110.
[14]	LI Jingdong, ZHU Jianjiao, ZHANG Lixin, XIONG yongfu. Laparoscopic radical resection of hilar cholangiocarcinoma: controversy and consensus* [J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 115-119.
[15]	CHEN Danlei, SHAO Chenghao. Controversy in minimally invasive treatment of distal cholangiocarcinoma and key technical points [J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 120-123.